Trillium Therapeutics Inc. closed a nonbrokered private placement of 1,950,000 common shares and 400,000 series II nonvoting convertible first preferred shares, both priced $8.50 apiece.
The company raised gross proceeds of about $20 million and plans to use net proceeds for product candidate development, working capital and general corporate purposes.
Cowen acted as sole placement agent.
